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In the dermis, ﬁbroblasts play an important role in the turnover of the dermal extracellular matrix. Collagen I and III, the most
importantdermalproteinsoftheextracellularmatrix,areprogressivelyalteredduringageinganddiabetes.Formimickingdiabetic
conditions, the cultured human dermal ﬁbroblasts were incubated with increasing amounts of AGE-modiﬁed BSA and D-glucose
for 24 hours. The expression of procollagen α2(I) and procollagen α1(III) mRNA was analyzed by quantitative real-time PCR.
Our data revealed that the treatment of ﬁbroblasts with AGE-modiﬁed BSA upregulated the expression of procollagen α2(I) and
procollagen α1(III) mRNA in a dose-dependent manner. High glucose levels mildly induced a proﬁbrogenic pattern, increasing
the procollagen α2(I) mRNA expression whereas there was a downregulation tendency of procollagen α1(III) mRNA.
Copyright © 2008 Serban Iren Andreea et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Elevated levels of blood glucose give birth to a vicious
cycle of metabolic disturbances within the intracellular
and extracellular environment and lead to a broad array
of diabetes complications. In the hyperglycemic milieu
activation of the aldose reductase pathway (AR), protein
kinase C (PKC), especially the β-isoform, and generation
of advanced glycation end products (AGEs) can be noticed
[1]. In ageing, the nonenzymatic glycosylation of proteins
or Maillard reaction occurs, which is a consequence of
the elevated levels of glucose and is accelerated in diabetes
[2]. The glycation reaction starts when the amino groups
of a protein react nonenzymatically with glucose to forma
Schiﬀ base, stabilized through Amadori rearrangement, and
it represents an early temporary step in the glycation process.
In the advanced stage, complex reactions that lead to the
formation of AGEs occur [3]. In ageing and diabetes, the
AGEs levels of long life proteins of the extracellular matrix
are increased [4]. These products cause cellular dysfunctions
by multiple mechanisms, including receptor-independent
andreceptor-dependentprocesses,andcandirectlyinﬂuence
the structural integrity of the vessel wall and underlying
basement membranes through excessive cross-linking of
matrix molecules such as collagen and through disruption
of matrix-matrix and matrix-cell interactions [5]. The
formation of AGEs in skin collagen favors cross-linking
reactions, resulting in decreased degradability and impaired
dermal regeneration [6]. AGEs can bind to ﬁbroblast cell
membranes and may contribute to the progression of skin
ageing [7].
The receptor for AGE (RAGE) is a multiligand recep-
tor belonging to the immunoglobulin superfamily found
in a widerange of cell types, including endothelial cells
(EC), mononuclear phagocytes (MP), lymphocytes, vascular
smooth muscle (VSMC), and neurons [8]. Recently, it was
demonstrated that RAGE is highly expressed in skin and
upregulatedbyAGEs andtumornecrosis factor-alpha(TNF-
α)[ 9].
Collagen type I and III are the major structural compo-
nentsofthedermalextracellularmatrix(ECM),representing
over 70% and, respectively, 15% of skin dry weight and
providing the dermis with tensile strength and stability [10].
Collagen metabolism is a complex process requiring a bal-
ance between synthesis and degradation through the action
of cytokines and matrix metalloproteinase (MMPs). The2 Experimental Diabetes Research
most important proﬁbrogenic cytokine is the transforming
growth factor-beta (TGF-β1) [11].
The aim of this study was to investigate the inﬂuence
of high glucose concentration and AGEs mimicking diabetic
conditions on procollagen 1 α2( P C o l1α2) and procollagen
3 α1( P C o l3α1) genes expression in cultured human skin
ﬁbroblasts.
2. MATERIALS AND METHODS
2.1. Preparationandidentiﬁcationof
AGE-modiﬁedBSA
Solutions of 1.6M D-glucose (Sigma-Aldrich company) and
100mg/mL bovine serum albumin (BSA Sigma-Aldrich,
RIA grade, fraction V) have been coincubated insterile
PBS 10mM, pH 7.4 (Gibco) for 6 weeks under aerobic
conditions at 37◦C, in the presence of 3mM NaN3 (Merck)
to prevent bacterial growth [12]. Controls with BSA solution
only were simultaneously kept under the same conditions.
After 6 weeks, the free sugar was removed by dialysis
against 10mM PBS, pH 7.4 for 48 hours. The protein
concentration (70mgBSA/mL) was determined by Bradford
method [13]. The formation of AGE-modiﬁed BSA (AGE-
BSA) was analyzed by fast protein liquid chromatography
(FPLC), SDS-PAGE, and by ﬂuorescence spectroscopy.
Fastproteinliquidchromatography
An FPLC automated system (¨ AKTA FPLC-Amersham Phar-
macia Biotech) with a size exclusion column (Superdex 200
HR 10/30) was used for separation of glycated and ungly-
cated BSA. The samples of 1.55μg/μL prepared in 10mM
PBS pH 7.4 were eluted in 5% acetonitrile (Merck) and
10mM PBS pH 7.4, at a constant ﬂow rate of 0.8mL/min,
and their absorption at 280nm was automatically recorded.
Gelelectrophoresis
AGE-BSA cross-linking and aggregation was investigated by
7.5% SDS-PAGE) with Mini Protean Bio-Rad equipment
[14] and protein bands were stained by Coomassie Brilliant
Blue R-250 (Sigma-Aldrich).
AGE-BSAlinkedﬂuorescenceassay
The ﬂuorescence detection of Maillard compounds was
done using the parameter λex370nm/λem440nm and for
pentosidine-like products, λex335nm/λem385nm was used.
The ﬂuorescence emission spectra between 380 and 600nm
(370nm excitation) and between 350 and 500nm (335nm
excitation) were scanned using a JASCO FP 750 spectroﬂuo-
rometer [15].
2.2. Cellculture
Human dermal ﬁbroblasts were obtained from skin biopsy
sampled from the inferior pubian region of young normal
female patients (average age 30±2.3 years) by employ-
ing explants technique [16]. All patients gave informed
written consent to tissue collection, which was conducted
under a protocol approved by the Ethical Commission
of National Institute of Endocrinology C.I. Parhon. The
cells (2×104/mL) were grown in DMEM (Sigma-Aldrich)
medium supplemented with 10% fetal bovine serum
(Sigma-Aldrich), sterile antimycotic solution 1X: peni-
cillin 100IU/mL, streptomycin0.1mg/mL and amphotericin
0.25μg/mL (Sigma-Aldrich), D-glucose 5.5mM, 2% glu-
tamine (Sigma-Aldrich), 0.22% NaHCO3 (Sigma-Aldrich),
and 0.47% HEPES (Sigma-Aldrich) in a 5% CO2 humidiﬁed
atmosphere, at 37◦C.
2.3. Treatmentofcells
The 70% conﬂuent ﬁbroblasts cultures (passage 3–5) were
maintained 24 hours in the growth medium containing
0.5% fetal bovine serum for synchronization of cells cycle.
Then they were treated with varying amounts of D-glucose:
5.5mM (normoglycemic), 11mM, 22mM, and 33mM
(hyperglycemic)for24hours.Theosmolarityofthemedium
was adjusted with D-mannitol after the addition of glucose,
in order to have the same osmolarity in all samples. Other
ﬂasks of cells were treated with diﬀerent amounts of sterile
AGE-modiﬁed BSA, and BSA was added in order to adjust
the total protein concentration to 5mg/mL. The eﬀect of
D-glucose, D-mannitol, or AGE-BSA on cell viability was
assessed by estimating the percent of cells excluding Trypan
blue. There was no signiﬁcant eﬀect of D-glucose, D-
mannitol, or AGE-BSA on cells viability. Over 95% of the
cells excluded the dye.
2.4. Real-timePCRforcollagentypeIandIII
genesexpression
RNA of treated cells was extracted using TRI Reagent kit
(Sigma-Aldrich) according to the manufacturer’s recom-
mendations [17] and by Chomezynski method [18]. RNA
integrity and purity were electrophoretically veriﬁed by
ethidium bromide staining and by OD260/OD280 nm absorp-
tion ratio. The speciﬁc sense and antisense oligonucleotide
primersfortargetgenesandforreferencegene(Table 1)wer e
designed with Beacon Designer programs (Premier Biosoft),
based on the published genes sequences. 1μg aliquots of
total RNA of each sample were reverse-transcribed into
cDNA using Bio-Rad iScript cDNA Synthesis Kit, following
the recommendations of the supplier. Real-time PCR was
performed in the Bio-Rad iCycler iQTM in a ﬁnal reaction
mixture of 25μL consisting of 4μL diluted template cDNA,
12.5 Bio-Rad 2x iQ SYBERTM Green Supermix, and 10pmol
of each forward and reverse primers (Applied Biosystems).
The following real-time PCR experimental run protocol
was used: denaturation program (95◦Cf o r8m i n u t e s ) ,
ampliﬁcation, and quantiﬁcation program repeated 45 times
(95◦C for 30 seconds, 54◦C for 30 seconds, and 72◦Cf o r3 0
seconds with a single ﬂuorescence measurement), melting
curve program repeated 80 times for 10 seconds (55◦C–95◦C
with a heating rate of 0.5◦C per second and a continuous
ﬂorescence measurement). Melting curve analysis showed a
single product for each transcript with melting temperaturesSerban Iren Andreea et al. 3
Table 1: Sequences of human primers used for real-time PCR.
Gene (mRNA) Oligonucleotide primer sequence (5 -3 ) Ampliﬁcation fragment Annealing temperature (◦C)
Calculate Use
Procolagen 1 α2 (PCol 1α2) sense GTGGTTACTACTGGATTGACC 331 53.4 54
Procolagen 1α2 (PCol1α2) antisense TTGCCAGTCTCCTCATCCAT
Procolagen 3α1 (Pcol3α1) sense GGAGTAGCAGTAGGAGGAC 91 54 54
Procolagen 1α1 (PCol3α1) antisense AACCAGGATGACCAGATGTA
18S RNA sense CTCAACACGGGAAACCTCAC 133 53.5 54
18S RNA antisense TTATCGGAATTAACCAGACAAATCG
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Figure 1: Fluorescence emission spectra in RFU (relative ﬂuorescence units)/1mg BSA; 6 weeks incubation of BSA (100mg/mL) at 37◦Ci n
PBS 10mM pH 7.4; curve (1) unglycated BSA (control); curve (2) BSA+1.6M D-glucose (AGE-modiﬁed BSA). (a) Fluorescence emission
spectra of samples at 335nm excitation. (b) Fluorescence emission spectra of samples at 370nm excitation.
as follows: for PCol 1α2, 89◦C; for PCol 3α1, 91◦C; and for
18 S RNA,8 9 ◦C. In order to calculate the relative expression
ratio (R)[ 19]o ft a r g e tg e n e s( PCol 1α2 and PCol 3α1)v e r s u s
a reference gene, (18 S RNA) it was necessary to determine
the crossing points (CPs) or cycle threshold (CT), the real-
time PCR ampliﬁcation eﬃciencies (Es), and the linearity
for each transcript (CT is deﬁned as the number of cycle
at which the ﬂuorescence signal is greater than a deﬁned
threshold in the logarithmic phase of ampliﬁcation). Real-
time PCR eﬃciencies were calculated from the given slope of
ac a l i b r a t i o nc u r v eC T= f(dilution series of cDNA for each
gene) in iCycler iQTM software, according to the equation:
E = 10(−1/slope),( 1 )
see [20]. The investigated transcripts showed good real-time
PCR eﬃciency rates for 1.93 PCol 1α2,2 . 1 2f o rPCol 3α1,a n d
1.89 for 18 S RNA with high linearity (Pearson correlation
coeﬃcient r =0.998). Generally, the relative expression ratio
(R) of the target gene is calculated based on E and
CT deviation of a sample versus a control and expressed
in comparison with a reference gene according to Pfaﬄ
equation [19]:
R =
(Etarget)
ΔCTtarget(control-sample)
(Eref)
ΔCTref(control-sample) ,( 2 )
where Etarget is the real-time PCR eﬃciency of target gene
transcript, Eref is the real-time PCR eﬃciency of a reference
gene transcript, ΔCTtarget is the CT deviation of control-
sample of target gene transcript, and ΔCTref is the CT
deviation of control-sample of reference gene transcript.
All experiments were done twice and samples were run
in triplicate each time, the data having been expressed as
the means±standard deviation. The statistical signiﬁcance
of diﬀerences between the experiments was evaluated using
Student’s t-test. P values <.05 were considered to be
statistically signiﬁcant.
3. RESULTS
3.1. EvidenceofAGE-modiﬁedBSAformation
The AGEs content in the preparations was assessed by
ﬂuorescence measurements, SDS-PAGE analysis, and gel
ﬁltration studies.
Fluorescenceassays
The ﬂuorescence level measured at 385nm emission wave-
length after a 335nm excitation wavelength was 3.77 ﬂu-
orescence units (RFU) for control BSA and 74.9 RFU for
AGE-BSA (Figure 1(a)). At 440nm emission after a 370nm
excitation was 3.7 RFU for control BSA and 65.7 RFU for4 Experimental Diabetes Research
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Figure 2: (a) and (b): SDS-PAGE electrophoretic proﬁles of 6 weeks glycation of BSA (100mg/mL) at 37◦C in PBS 10mM pH 7.4; lanes 1
and3:BSA+1.6D-glucose(AGE-modiﬁedBSA)(loadedwith10μgand5μgprotein,resp.);lanes2and4:unglycatedBSA(control)(loaded
with 10μg and 5μg protein, resp.); lane 5: molecular weight marker (MWM 105 Bio-Rad). This was carried out using a 4% stacking and
7.5% resolving gel and Coomassie blue staining. (c) Corelation MW-RF.
AGE-BSA. All ﬂuorescence recorded was done at 1mg/mL
protein (Figure 1(b)).
Gelelectrophoresis
SDS-PAGE analysishasshown the formationofanAGE-BSA
monomer of 77.049kDa and a 155.84kDa dimer, whereas
the monomer of control BSA was of 68.66kDa (Figure 2).
Chromatographicstudies
The FPLC elution pattern of BSA control sample showed
only one peak corresponding to a 67.96kDa molecular
weight (retention volume 13.20mL), while the glycated
BSA (AGE-BSA) presented two peaks of 83.29kDa (reten-
tion volume 12.78mL) and 161.46kDa (retention volume
10.81mL). The peak with the retention volume at 12.78mL
showed a slightly increase in molecular weight and a major
increase in 280nm absorbance in comparison with the
unglycated BSA peak. The peak with the retention volume
10.81mLcorrespondstoadimerwithhighmolecularweight
of 161.46kDa of the glycated BSA monomer of 83.29kDa
(Figure 3). The increase in molecular weight of glycated
BSA monomer and the formation of glycated BSA dimer
with a higher molecular mass is probably due to the ability
of AGEs compounds to generate intra- and intermolecular
cross-linkings.Chromatographicdataareinaccordancewith
the SDS-PAGE results.
3.2. Inﬂuenceofhighglucoseconcentrationonthe
expressionofprocollagentypeIandIIIin
culturedhumandermalﬁbroblasts
The inﬂuence of high glucose concentration (mimicking
diabetic conditions) on steady-state levels of the procollagen
1 α2 and procollagen 3 α1 mRNA was determined. Conﬂuent
monolayer ﬁbroblasts were treated with 11mM, 22mM,
and 33mM D-glucose for 24 hours. The same type of cells
treated with 5.5mM D-glucose (normoglycemic conditions)
was used as control. The mRNA expression was analyzed
by quantitative real-time PCR relative to 18 S RNA. The
high level in glucose compared to the control (5.5mM
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Figure 3: FPLC separation of glycated BSA on Superdex 200 HR
10/30 column, 155μg protein/100μL injection volumes: 6 weeks
incubation of BSA (100mg/mL) at 37◦C in 10mM PBS pH 7.4;
curve (1) BSA+1.6M D-glucose (AGE-modiﬁed BSA); curve (2)
unglycated BSA (control).
glucose) resulted in a moderate increase of the relative
expression ration (R)o fp r o c o l l a g e nα2(I) as follows: at
11 and at 22mM glucose, the relative expression ratio (R)
increased to 1.33±0.051-fold (P<.05) and to 1.28±0.048-
fold(P<.05),respectively,andat33mMglucosetheincrease
was 1.64±0.063-fold P<.02. In the case of procollagen
α1(III)mRNAatallconcentrationofglucoseusedinthecells
treatment,therewasatrendfordownregulationcomparedto
the control (Figure 4).
3.3. EffectofAGE-modiﬁedBSAon
theexpressionofprocollagentypeIandIIIin
culturedhumandermalﬁbroblasts
Conﬂuent monolayers human skin ﬁbroblasts were exposed
to increasing concentrations of AGE-modiﬁed BSA or BSA
as control in culture medium containing 0.5% fetal bovine
serumfor24 hoursand mRNAexpression for procollagen1α2
and procollagen3α1 was determined by real-time PCR.
The treatment with increasing AGE-BSA levels adjusted to
concentrations of 5mg/mL protein with BSA upregulatedSerban Iren Andreea et al. 5
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Figure 4: The relative expression ratios (R)f o rprocollagen 1α2 and
forprocollagen3α1genesafter24hoursglucosetreatmentofculture
human dermal ﬁbroblasts. R was expressed in arbitrary units. The
data are shown as the mean±SD for two independent experiments
run in triplicate each time with signiﬁcant diﬀerences compared to
control (5.5mM glucose) at ∗ P<.05, ∗∗ P<.02, and ∗∗∗ P<.01.
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Figure 5: The relative expression ratios (R)f o rprocollagen 1α2 and
for procollagen 3α1 genes after 24 hours incubation with AGE-BSA
of culture human dermal ﬁbroblasts. R was expressed in arbitrary
units. The data are shown as the mean±SD for two independent
experiments run in triplicate each time with signiﬁcant diﬀerences
compared to control (5mg/mL BSA) at ∗ P<.05 and ∗∗∗ P<.01.
the mRNA expression of procollagen α2(I) and procollagen
α1(III) compared to the control (5mg/mL BSA) (Figure 5).
In response to 1mg/mL of AGE-BSA, the relative expression
ratio(R) for procollagen α2( I )w a s2 . 0 3±0.15-fold (P<.05)
and for procollagen α1(III) was 3.4±0.3-fold (P<.05) on
average. In the case of 2mg/mL AGE-BSA treatment, the
real upregulation ratio was, on average, 3.57 ± 0.26-fold
(P<.05) and 6.22±0.27 (P<0.01) for procollagen α2( I )
and, respectively, for procollagen α1(III). The treatment
of cultured dermal ﬁbroblasts with 4mg/mL AGE-BSA
increased relative expression ratio (R)t o4 . 1 4 ±0.14-fold
(P<.01) and to 7.4±0.32-fold (P<.01) for procollagen
α2(I) and, respectively, for procollagen α1(III). These results
showed that AGE-BSA upregulated the procollagen α1(III)
mRNA expression to a great extent in comparison to
procollagen α2(I) mRNA expression and this stimulation
appeared to have a dose-dependent eﬀect.
4. DISCUSSION
Tissue remodeling of extracellular matrix (ECM) is an
essential and dynamic process associated with physiological
responsesanditinvolvestheproductionanddepositofnewly
synthesized ECM components, as well as the degradation
of ECM. The balance of these processes results in either
preservation or alteration of the structure and functions of
the support tissue [21]. Resorption of the ECM is mediated
by MMPs, whereas generation of ECM is predominantly
achieved through the production of collagen. Degradation
of ECM generally characterizes pathological states such as
arthritisortumorinvasion,whereastheincreasedgeneration
ofECMunderliesﬁbroticdiseases.Bothprocessesarestrictly
regulated by complex networks of cellular and molecular
interaction [22]. Mediators such as the proﬁbrotic cytokines
(TGF-β1, interleukins, and connective tissue growth factor-
CTGF) released by resident cells, for examples, skin ﬁbrob-
lasts, or inﬁltrating leukocytes, monocytes, or macrophages
may play a central role in the turnover of the dermal
ECM. Expansion of ECM in ﬁbrosis occurs in many tissues,
including skin, as part of the end-organ complications in
diabetes and chronic hyperglycemia. The formation of AGEs
is considered as causative factor in diabetic tissue ﬁbrosis.
Elevated levels of blood glucose ignite a vicious cycle of
metabolic disturbances with activation of multiple pathways.
For example, it was demonstrated that AR is implicatedin
the adverse cellular response to high levels of glucose [23].
Multiple studies indicate that expression and activity of AR
are increased in experimental models and human tissuesin
diabetes, including the diabetic kidney [24]. In addition to
AR, isoforms of protein kinase C family, especially PKCβ
isoform, has been associated with enhanced activity in
hyperglycemia [25]. In vivo, pharmacologic blockade of
PKCβ hasbeenassociatedwithimprovedvascularfunctionin
diabeticrats, as well as amelioration of accelerated mesangial
expansion and expression of genes such as TGF-β1a n d
extracellular matrix components [11]. Our results suggest
that high levels of glucose may inﬂuence the expansion
of ECM and the process of skin aging through mild
stimulation of procollagen1α2 gene expression and possibly
of other ECM proteins. A potential mediator for this eﬀect
is probably TGF-β1, which is regulated by PKCβ.I n c r e a s e d
glucose ﬂux through glycolysis and AR pathway leads to
increased intracellular NADH/NAD+ ratio, which causes an
inhibition of NAD+-dependent enzyme glyceraldehydes-3-
phosphate dehydrogenase (GAPDH), which in turn will
result in an increase in the dihydroxyacetone phosphate and
glyceraldehyde-3-phosphate levels. These triosephosphates
can be converted into PKC activator diacylglycerol, transfor-
mation accelerated by the increase in NADH/NAD+ ratio.6 Experimental Diabetes Research
Another consequence of elevated levels of glucose is the
Maillard reaction. In the advanced step, complex reactions
that lead to the formation of AGEs occur [26]. Numerous
studies have suggested a link among glucose-modiﬁed
proteins, Amadori products, AGE, and activation of PKCβ
isoforms. In cultured mesangial cells, inhibitors of PKCβ
isoforms prevented the glycated albumin-induced increased
expression of collagen IV [27]. Some in vivo studies showed
that infusion of AGE-modiﬁed murine serumal bumin
into nondiabetic mice for 4 weeks caused upregulation
of glomerular α1(IV) collagen, laminin β1, and TGF-β1
transcriptionin the kidney [28].
In our experimental conditions, the AGE-modiﬁed BSA
concentrations used appeared to be high, but the doses used
in the treatment of cells (1, 2, and 4mg/mL) represent the
concentration of glycated protein not of AGEs products. By
ﬂuorescence, gel ﬁltration chromatography, and SDS-PAGE
assays, we have highlighted the formation of AGEs and the
cross-linking of glycated BSA but we did not measure the
levelofAGEscompounds.Ontheotherhand,ﬁbroblastscan
suﬀerinvivodirectlyfromtheeﬀectsofAGEsformedduring
the degradation of matrix proteins that have a long life and
important amounts of these compounds can accumulate in
time.
Finally, by means of real-time PCR, we revealed that
AGE-modiﬁed BSA interacts with cultured human dermal
ﬁbroblasts and inﬂuence their function by signiﬁcant upreg-
ulation in a dose-dependent manner of both procollagen
1α2 and procollagen 3α1 genes expression. In addition, at all
AGE-BSA doses used for the cultured ﬁbroblasts treatments,
the ratio of procollagen α1(III)/procollagen α2(I) mRNA
remained constant to approximately 1.7 on average.
This could probably alter the turnover of collagenous
ECM in the skin and contribute to a decreased tensile
strength and mechanical stability of connective tissues and a
diﬃcult healing in diabetes. Twigg et al. [29]h a v e r e p o r t e d
that in conﬂuent monolayers of cultured human dermal
ﬁbroblasts, the connective tissue growth factor (CTGF) is
upregulated at the mRNA and protein levels by AGEs.
Later, they have shown that CTGF contributes signiﬁcantly,
in human dermal ﬁbroblasts, to AGEs upregulation of
ﬁbronectin, another ECM component like collagen, through
a PKC-dependent mechanism [30]. In the same year Okano
et al. [7] demonstrated that AGEs which are accumulating
in elastin, ﬁbronectin, and collagens bind to ﬁbroblast
membranesatconcentrationsof2.5–40mg/mL.Ourdataare
in accord with other studies which described AGEs increased
collagen production in normal rat kidney ﬁbroblasts [31].
Recently, Lohwasser et al. demonstrated for the ﬁrst time
that RAGE protein is highly expressed in human skin
and in cultured human skin ﬁbroblasts and AGE adduct
upregulated RAGE expression and induced signiﬁcantly
upregulated expression of CTGF, TGF-β1, and procollagen
α1(I)[9].AlsoRAGEinductionthroughAGE-BSAandTNF-
αwasshownbeforeinhumanumbilicalveinendothelialcells
[32] and through AGE-BSA in normal rat kidney ﬁbroblasts
[31].
It seems that the most important ECM-related protein
genes Pcol 1α2 and Pcol 3α1 are upregulated in the presence
of AGEs and to a less extent by high levels of glucose
in cultured human dermal ﬁbroblast possibly by receptor-
independent/dependent pathways.
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